Found a treatment that improves effectiveness against a type of anemia
The Bellvitge Institute for Biomedical Research (IDIBELL) participated in a study that reveals that adding the drug Eltrombopag to conventional therapy with immunosuppressants autoimmune aplastic anemia “significantly improves the effectiveness” of the treatment.
The study, published in the magazine “The New England Journal of Medicine”, corresponds to a phase 3 clinical trial which had the participation of the group leader at IDIBELL and head of the clinical hematology service of the Catalan Institute of oncology (ICO) of L’Hospitalet de Llobregat (Barcelona), Anna Sureda.
What is aplastic anemia?
Aplastic anemia is a bone marrow disorder which prevents the formation of blood cells and produces tired, susceptibility at infections Yes bleedingexplained IDIBELL in a press release.
Many factors are at the origin of this type of anemia: treatments with chemotherapyexposure to toxic substancesviral infections, among others, but the most frequent are autoimmune diseases that prevent the proper functioning of the bone marrow.
Immunosuppressive therapy is standard therapy to deal with aplastic anemia because it reduces the attack of the immune system on the bone marrow itself.
However, the the effectiveness of these drugs to reduce anemia is limited and between 10% and 15% of cases may be the cause of some kind of myeloid cancer.
Considerable improvement without additional side effects
The results of the study show that the drug combination the percentage of patients who respond to treatment increases from 41% with only immunosuppressants to 68% with the addition of Eltrombopag.
Too much improves treatment response time going from almost nine months to three, and all without showing any additional side effects.
“Over the past thirty years, none of the efforts to improve therapy for aplastic anemia have been successful. This work shows for the first time a significant improvement in the quality and speed of hematological recovery,” Sureda celebrated.